Buchumschlag

SARS-CoV-2 vaccination in primary humoral immunodeficiency: experience from a german lung clinic

Introduction: During the COVID-19 pandemic, the effectiveness of vaccines against SARS-CoV-2 in immunodeficient patients not only did affect the individual risk of these vulnerable patients but endangered the selection of new variants of concern due to prolonged virus shedding by these patients. Met...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Rosendahl, Sophie (VerfasserIn) , Trudzinski, Franziska (VerfasserIn) , Polke, Markus (VerfasserIn) , Herth, Felix (VerfasserIn) , Kreuter, Michael (VerfasserIn) , Giese, Thomas (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: May 2025
In: Respiration
Year: 2025, Jahrgang: 104, Heft: 5, Pages: 349-359
ISSN:1423-0356
DOI:10.1159/000543146
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000543146
Volltext
Verfasserangaben:Sophie Rosendahl, Franziska C. Trudzinski, Markus Polke, Felix J.F. Herth, Michael Kreuter, Thomas Giese
Beschreibung
Zusammenfassung:Introduction: During the COVID-19 pandemic, the effectiveness of vaccines against SARS-CoV-2 in immunodeficient patients not only did affect the individual risk of these vulnerable patients but endangered the selection of new variants of concern due to prolonged virus shedding by these patients. Methods: In a tertiary center for pulmonary diseases, we investigated the immune response of 11 patients with primary humoral immunodeficiency and 13 healthy controls on the humoral and cellular level after full vaccination with an mRNA or vector vaccine against SARS-CoV-2. Results: In the majority of patients (73%), we found antibodies against the spike protein above the threshold of positivity. Likewise, patients showed a promising cellular response: the upregulated production of INFγ, TNFα, and CXCL10 by T cells did not differ from the response of healthy controls. Conclusion: These results stress the importance to further discern an adequate immunological correlate of protection and the need to follow the effect of booster immunizations in this population at risk.
Beschreibung:Veröffentlicht: 19. Dezember 2024
Gesehen am 25.07.2025
Beschreibung:Online Resource
ISSN:1423-0356
DOI:10.1159/000543146

Ähnliche Einträge